2026-10-18T23:16:34Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/154402026-10-18T21:14:24Zopenairedrivercom_ebyu_10000col_ebyu_10001

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinomaKulhan, MehmetKulhan, GozdeNayki, UmitNayki, CenkUlug, PasaSipahi, MehmetYildirim, YusufClear-cell carcinomaEndometrial tumorsPapillary cell carcinomaAdenocarcinoma, Clear CellAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCA-125 AntigenCarcinoma, PapillaryEndometrial NeoplasmsFemaleGravidityHumansLymphatic MetastasisMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalParityRadiotherapy, AdjuvantSurvival Analysisantineoplastic agentCA 125 antigenadenocarcinomaadjuvant radiotherapyblooddrug therapyendometrium tumorhumanlymph node metastasismortalityObjectives: We aimed to evaluate and compare the clinical and pathological features, diagnosis, treatment, and prognosis of uterine papillary serous carcinoma (UPSC) and clear-cell carcinoma (CC). Material and methods: Thirty-four patients who were operated on for UPSC and CC carcinoma at the Izmir Tepecik Research and Teaching Hospital, between January 1983 and December 2014, were included. Patients were evaluated for the following factors: Age, gravidity, parity, preoperative CA-125, tumor size, myometrial and lymphovascular invasion, lymph node tumor metastasis, presence of atypical cells in peritoneal cytology, pathology results, operation types, whether or not they received postoperative adjuvant therapy, prognosis, and death rate. Results: The stage of the disease was the main factor affecting disease-free and the overall survival. Cisplatin-based chemotherapy was partially effective in patients with postoperative recurrence, while postoperative adjuvant radiotherapy proved to be more effective in preventing relapse. Conclusion: The studied parameters generally were concordant with the literature but, due to the relatively small sample size, more comprehensive and multicenter studies are needed to generate valid results. © 2016 Via Medica.Studio K Krzysztof Molenda2016Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/15440https://doi.org/10.5603/gp.2016.00460017-0011enGinekologia Polskainfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15440